

Innovent, Eli Lilly presents co-developed cancer-fighting Tyvyt at CIIE 2019

02 December 2019 | News

The new medical breakthrough, the result of the cooperation between the two companies, provides global patients with a more effective, safer treatment solution to fight cancer



Innovent Biologics, a multinational biopharmaceutical company, and Eli Lilly and Company presented their co-developed Tyvyt® (generic name: sintilimab injection), a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody at CIIE 2019. The medicine works to block the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently help patients restore the endogenous anti-tumour T-cell response. The new medical breakthrough, the result of the cooperation between the two companies, provides global patients with a more effective, safer treatment solution to fight cancer.

The world-leading anti-PD-1 inhibitor, Tyvyt® has been granted approval for market authorization by the National Medical Products Administration of China ("NMPA", formerly the China Food and Drug Administration) for the treatment of patients with classical cHL or relapsed or refractory r/r cHL Hodgkin's lymphoma following two or more lines of systemic chemotherapy. It also has been selected into the Guidelines of Chinese Society of Clinical Oncology (CSCO) for Lymphoid Malignancies in 2019. Sintilimab injection is currently undergoing 20 clinical studies, 8 of which are registered clinical trials, to explore its application for a variety of solid tumors.

To push the boundaries of global cooperation, Innovent Biologics established a strategic alliance with Eli Lilly and Company covering research, registration, production and market development, helping Chinese medical institutes to bring in new concepts on the journey to going global.

Innovent Biologics has formed a groundbreaking biotech drug development collaboration with Eli Lilly since 2015. In the joint efforts to address the growing burden of cancer, the two companies are set to collaborate on the development and commercialization of at least three sintilimab-based cancer treatments over the next decade.

As part of a new partnership for developing the next-generation drugs of cancer immunotherapy, Eli Lilly is leading medical research and working with Innovent to introduce high-quality and affordable cancer-fighting products to China's market.